Edgewise Therapeutics (EWTX) Cash from Financing Activities (2020 - 2026)

Edgewise Therapeutics has disclosed Cash from Financing Activities across 7 years of filings, most recently posting $12.2 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $12.2 million, up 447.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $206.0 million (up 1880.56% YoY), and the FY2025 annual result was $196.1 million, down 21.33% from the prior year.
• Cash from Financing Activities came in at $12.2 million for Q1 2026 at Edgewise Therapeutics, up from $4.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $241.1 million in Q1 2024 to a low of -$303000.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $2.2 million (2025), against an average of $37.7 million.
• Across the five-year window, Cash from Financing Activities sank 203.41% in 2022 and jumped 1147866.67% in 2024, its largest moves.
• Edgewise Therapeutics' Cash from Financing Activities stood at -$303000.0 in 2022, then soared by 17587.46% to $53.0 million in 2023, then slumped by 94.54% to $2.9 million in 2024, then soared by 37.31% to $4.0 million in 2025, then soared by 206.24% to $12.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $12.2 million (Q1 2026), $4.0 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.